Celularity Inc. Class A Common Stock CELU
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-07T07:43:35.849Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T23:09:44.815844854Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-07T07:43:34.803606+00:00
Celularity Inc. Class A Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 0.62 | 748.3% | 84.6% | |||
| 25Δ | 7.22 | 800.0% | 858.9% | 0.73 | 699.8% | 70.2% |
| 30Δ | 5.81 | 800.0% | 703.5% | 0.84 | 651.4% | 55.8% |
| 35Δ | 4.72 | 800.0% | 578.4% | 0.95 | 602.9% | 41.3% |
| 40Δ | 4.08 | 800.0% | 494.2% | 1.06 | 568.5% | 32.8% |
| 45Δ | 3.43 | 800.0% | 410.0% | 1.16 | 544.9% | 28.7% |
| 50Δ | 2.78 | 800.0% | 325.8% | 1.27 | 521.3% | 24.7% |
| 55Δ | 2.13 | 800.0% | 241.6% | 1.37 | 497.7% | 20.7% |
| 60Δ | 1.47 | 474.1% | 16.6% | |||
| 65Δ | 0.85 | 563.6% | 47.8% | 1.60 | 455.0% | 13.6% |
| 70Δ | 0.76 | 621.1% | 43.4% | 1.73 | 437.5% | 11.0% |
| 75Δ | 0.68 | 678.6% | 39.0% | 1.87 | 419.9% | 8.4% |
| 80Δ | 0.59 | 736.1% | 34.5% | 6.51 | 715.8% | 9.1% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.62
- IV
- 748.3%
- B/E move
- 84.6%
25Δ
- Pseudo strike
- 7.22
- IV
- 800.0%
- B/E move
- 858.9%
- Pseudo strike
- 0.73
- IV
- 699.8%
- B/E move
- 70.2%
30Δ
- Pseudo strike
- 5.81
- IV
- 800.0%
- B/E move
- 703.5%
- Pseudo strike
- 0.84
- IV
- 651.4%
- B/E move
- 55.8%
35Δ
- Pseudo strike
- 4.72
- IV
- 800.0%
- B/E move
- 578.4%
- Pseudo strike
- 0.95
- IV
- 602.9%
- B/E move
- 41.3%
40Δ
- Pseudo strike
- 4.08
- IV
- 800.0%
- B/E move
- 494.2%
- Pseudo strike
- 1.06
- IV
- 568.5%
- B/E move
- 32.8%
45Δ
- Pseudo strike
- 3.43
- IV
- 800.0%
- B/E move
- 410.0%
- Pseudo strike
- 1.16
- IV
- 544.9%
- B/E move
- 28.7%
50Δ
- Pseudo strike
- 2.78
- IV
- 800.0%
- B/E move
- 325.8%
- Pseudo strike
- 1.27
- IV
- 521.3%
- B/E move
- 24.7%
55Δ
- Pseudo strike
- 2.13
- IV
- 800.0%
- B/E move
- 241.6%
- Pseudo strike
- 1.37
- IV
- 497.7%
- B/E move
- 20.7%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.47
- IV
- 474.1%
- B/E move
- 16.6%
65Δ
- Pseudo strike
- 0.85
- IV
- 563.6%
- B/E move
- 47.8%
- Pseudo strike
- 1.60
- IV
- 455.0%
- B/E move
- 13.6%
70Δ
- Pseudo strike
- 0.76
- IV
- 621.1%
- B/E move
- 43.4%
- Pseudo strike
- 1.73
- IV
- 437.5%
- B/E move
- 11.0%
75Δ
- Pseudo strike
- 0.68
- IV
- 678.6%
- B/E move
- 39.0%
- Pseudo strike
- 1.87
- IV
- 419.9%
- B/E move
- 8.4%
80Δ
- Pseudo strike
- 0.59
- IV
- 736.1%
- B/E move
- 34.5%
- Pseudo strike
- 6.51
- IV
- 715.8%
- B/E move
- 9.1%
Options history
No recorded observations
Biotechnology
CGEM
Description unavailable
More →CGON
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070, an oncolytic virus…
More →CHRS
Description unavailable
More →CING
Cingulate Inc., a clinical-stage biopharmaceutical company, is focused on developing candidate products for the treatment of neurobiological and central nervous system disorders.…
More →CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.…
More →CLYM
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. The company is headquartered in Wilmington, Delaware.
More →